Utah Medical Products AI Stock Analysis
Want to see UTMD full AI Analyst Report?
Utah Medical Products (UTMD) AI Stock Analysis
Utah Medical Products
(NASDAQ:UTMD)
The overall score of 74 reflects a company with a fortress-like balance sheet and strong cash generation, which provides a high floor for the rating. The primary positive catalyst is the recent Orion Medical acquisition, which is expected to immediately boost top-line growth and counter the persistent revenue declines that have been the main financial weakness. Technicals and valuation are neutral, contributing neither significant upside nor downside risk to the current outlook.
Utah Medical Products Key Performance Indicators (KPIs)
Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $208.07M
- Dividend Yield
- 1.70%
- Average Volume (3M)
- 36.95K
- Price to Earnings (P/E)
- 21.9
- Beta (1Y)
- 0.42
- Revenue Growth
- -9.62%
- EPS Growth
- ―
- Country
- US
- Employees
- 146
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Utah Medical Products Business Overview & Revenue Model
Company Description
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and d...
How the Company Makes Money
UTMD makes money by selling medical devices and related components to healthcare customers, generating revenue largely from product sales rather than services. A core driver is recurring demand for single-use/disposable products used in routine hospi...
Utah Medical Products Financial Statement Overview
Summary
Financial performance is solid, anchored by an exceptionally strong, debt-free balance sheet (95) and healthy cash flow conversion (80). Profitability remains high with a 29% net margin, though the multi-year revenue decline and margin compression weigh on the overall score, preventing a higher rating.
Income Statement
68PositiveBalance Sheet
95Very PositiveCash Flow
80Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.92M | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Gross Profit | 20.14M | 22.00M | 24.14M | 30.04M | 32.20M | 30.92M |
| EBITDA | 14.87M | 17.06M | 19.65M | 24.75M | 27.74M | 26.34M |
| Net Income | 10.64M | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
Balance Sheet | ||||||
| Total Assets | 128.50M | 122.54M | 122.54M | 135.46M | 123.87M | 115.64M |
| Cash, Cash Equivalents and Short-Term Investments | 85.20M | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total Debt | 180.00K | 225.00K | 338.00K | 295.00K | 341.00K | 396.00K |
| Total Liabilities | 5.22M | 3.27M | 5.11M | 7.14M | 9.62M | 8.50M |
| Stockholders Equity | 123.28M | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
Cash Flow | ||||||
| Free Cash Flow | 7.60M | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
| Operating Cash Flow | 7.97M | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Investing Cash Flow | -373.00K | -371.00K | -208.00K | -639.00K | -818.00K | -552.00K |
| Financing Cash Flow | -4.15M | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
Utah Medical Products Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 73.63 is above the 20-day moving average (MA) of 72.42, above the 50-day MA of 72.89, and above the 200-day MA of 68.05, indicating a bullish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 52.51 is Neutral, neither overbought nor oversold. The STOCH value of 91.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.
Utah Medical Products Risk Analysis
Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksUtah Medical Products Peers Comparison
Overall Rating
- UTMD74Outperform
INFU70Outperform
KRMD57Neutral
SMTI46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| UTMD | 74Outperform | $207.58M | 21.85 | 8.78% | 1.70% | -9.62% | ― |
| INFU | 70Outperform | $306.11M | 32.06 | 15.77% | ― | 2.40% | 76.01% |
| KRMD | 57Neutral | $145.90M | -219.77 | 0.00% | ― | 18.43% | 78.07% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SMTI | 46Neutral | $290.89M | -8.50 | -473.55% | ― | 12.93% | -219.19% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UTMD | Utah Medical Products | 73.63 | 19.30 | 35.51% | |
| INFU | InfuSystem Holdings, Inc. | 14.79 | 5.28 | 55.52% | |
| KRMD | Repro-Med Systems, Inc. | 3.69 | -0.63 | -14.58% | |
| SMTI | Sanara MedTech | 32.54 | 11.00 | 51.07% |
Utah Medical Products Corporate Events
Utah Medical Products Expands Via Orion Medical Acquisition
PositiveOn August 31, 2026, Femcare Ltd., a wholly owned subsidiary of Utah Medical Products, Inc., completed the acquisition of all common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of harm reduction medical device kits...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026